Literature DB >> 18325856

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

Thomas P C Dorlo1, Michel J X Hillebrand, Hilde Rosing, Teunis A Eggelte, Peter J de Vries, Jos H Beijnen.   

Abstract

A sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for the quantification of miltefosine is presented. A 250 microL human EDTA plasma aliquot was spiked with miltefosine and extracted by a solid-phase extraction method. Separation was performed on a Gemini C18 column (150 mm x 2.0 mm I.D., 5 microm) using an alkaline eluent. Detection was performed by positive ion electrospray ionization followed by triple-quadrupole mass spectrometry. The assay has been validated for miltefosine from 4 to 2000 ng/mL using 250 microL human EDTA plasma samples. Results from the validation demonstrate that miltefosine can be accurately and precisely quantified in human plasma. At the lowest level, the intra-assay precision was lower than 10.7%, the inter-assay precision was 10.6% and accuracies were between 95.1 and 109%. This assay is successfully used in a clinical pharmacokinetic study with miltefosine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325856     DOI: 10.1016/j.jchromb.2008.02.005

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  20 in total

1.  Minimal Cerebrospinal Fluid Concentration of Miltefosine despite Therapeutic Plasma Levels during the Treatment of Amebic Encephalitis.

Authors:  Marguerite L Monogue; Durward Watson; Julie S Alexander; Dominick Cavuoti; Laura M Doyle; Michael Zhuo Wang; Bonnie C Prokesch
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  A E Kip; H Rosing; M J X Hillebrand; M M Castro; M A Gomez; J H M Schellens; J H Beijnen; T P C Dorlo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-06-24       Impact factor: 3.205

3.  Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Authors:  Anke E Kip; María Del Mar Castro; Maria Adelaida Gomez; Alexandra Cossio; Jan H M Schellens; Jos H Beijnen; Nancy Gore Saravia; Thomas P C Dorlo
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

4.  Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Authors:  Sharon L Roy; Jane T Atkins; Rosemaria Gennuso; Danny Kofos; Rama R Sriram; Thomas P C Dorlo; Teresa Hayes; Yvonne Qvarnstrom; Zuzana Kucerova; B Joseph Guglielmo; Govinda S Visvesvara
Journal:  Parasitol Res       Date:  2015-09-02       Impact factor: 2.289

5.  Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Authors:  Thomas P C Dorlo; Pieter P A M van Thiel; Alwin D R Huitema; Ron J Keizer; Henry J C de Vries; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

6.  Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Authors:  Deepak Kumar Deep; Ruchi Singh; Arpita Kulshrestha; Saima Wajid; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

Authors:  Thomas P C Dorlo; Alwin D R Huitema; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

8.  Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

Authors:  Raymond Omollo; Neal Alexander; Tansy Edwards; Eltahir A G Khalil; Brima M Younis; Abuzaid A Abuzaid; Monique Wasunna; Njenga Njoroge; Dedan Kinoti; George Kirigi; Thomas P C Dorlo; Sally Ellis; Manica Balasegaram; Ahmed M Musa
Journal:  Trials       Date:  2011-06-30       Impact factor: 2.279

9.  Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.

Authors:  Thomas P C Dorlo; Pieter P A M van Thiel; Gerard J Schoone; Ymkje Stienstra; Michèle van Vugt; Jos H Beijnen; Peter J de Vries
Journal:  PLoS Negl Trop Dis       Date:  2011-12-13

10.  A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.

Authors:  Thomas P C Dorlo; Teunis A Eggelte; Gerard J Schoone; Peter J de Vries; Jos H Beijnen
Journal:  PLoS Negl Trop Dis       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.